Glucocorticoids, including dexamethasone, have been a mainstay of treatment for multiple
myeloma (MM) for decades. In current treatment protocols and NCCN clinical practice …

Glucocorticoids are a backbone of treatment for multiple myeloma in both the upfront and
relapsed/refractory setting. While glucocorticoids have single agent activity in multiple …

Background Glucocorticoids, particularly dexamethasone, are often used in combination
with novel agents in multiple myeloma. This study compared the safety, rate, and extent of …

Background: The use of low-dose dexamethasone (Dex) in combination with lenalidomide
(Len), an immunomodulatory compound, improves overall survival (OS) compared with high …

Dexamethasone (Dex), alone or in combination, is commonly used for treating multiple
myeloma. Dex as single agent for initial therapy of myeloma results in overall response rates …

Introduction: Selinexor is a novel, first-in-class selective inhibitor of nuclear export (SINE),
which blocks XPO1, forcing the nuclear retention and activation of tumor suppressor …

Despite the introduction of multiple new drugs and combination therapies, conventional
dexamethasone remains a cornerstone in the treatment of multiple myeloma (MM). Its …

Corticosteroid (steroid) medications are associated with challenging adverse effects that can
negatively impact patient quality of life. However, owing to a long legacy of effective use in …

8521 Background: We recently reported superior 1-yr prog. free survival (PFS) for pts with
NDMM treated with LD vs D alone. High-risk cytogenetic abnormalities (HRCA) confer poor …

Lenalidomide (Revlimid®) is approved for the treatment of previously treated multiple
myeloma (MM) in combination with dexamethasone. Single agent lenalidomide has direct …